Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/3906
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Merchant, T. E. | en |
dc.contributor.author | Klimo, P., Jr. | en |
dc.contributor.author | Boop, F. | en |
dc.contributor.author | Conklin, H. | en |
dc.contributor.author | Onar-Thomas, A. | en |
dc.contributor.author | Ellison, D. W. | en |
dc.contributor.author | Robinson, G. W. | en |
dc.contributor.author | Gajjar, A. | en |
dc.contributor.author | Liu, A. P. Y. | en |
dc.contributor.author | Wu, G. | en |
dc.contributor.author | Orr, B. A. | en |
dc.contributor.author | Lin, T. | en |
dc.contributor.author | Ashford, J. M. | en |
dc.contributor.author | Bass, J. K. | en |
dc.contributor.author | Bowers, D. C. | en |
dc.contributor.author | Hassall, T. | en |
dc.contributor.author | Fisher, P. G. | en |
dc.contributor.author | Indelicato, D. J. | en |
dc.date.accessioned | 2022-11-07T23:47:20Z | - |
dc.date.available | 2022-11-07T23:47:20Z | - |
dc.date.issued | 2021 | en |
dc.identifier.citation | Jan-Dec 3, (1), 2021, p. vdaa168 | en |
dc.identifier.other | RIS | en |
dc.identifier.uri | http://dora.health.qld.gov.au/qldresearchjspui/handle/1/3906 | - |
dc.description.abstract | BACKGROUND: Choroid plexus carcinoma (CPC) is a rare and aggressive tumor of infancy without a clear treatment strategy. This study describes the outcomes of children with CPC treated on the multi-institutional phase 2 SJYC07 trial and reports on the significance of clinical and molecular characteristics. METHODS: Eligible children <3 years-old with CPC were postoperatively stratified to intermediate-risk (IR) stratum if disease was localized or high-risk (HR) stratum, if metastatic. All received high-dose methotrexate-containing induction chemotherapy. IR-stratum patients received focal irradiation as consolidation whereas HR-stratum patients received additional chemotherapy. Consolidation was followed by oral antiangiogenic maintenance regimen. Survival rates and potential prognostic factors were analyzed. RESULTS: Thirteen patients (median age: 1.41 years, range: 0.21-2.93) were enrolled; 5 IR, 8 HR. Gross-total resection or near-total resection was achieved in ten patients and subtotal resection in 3. Seven patients had TP53-mutant tumors, including 4 who were germline carriers. Five patients experienced progression and died of disease; 8 (including 5 HR) are alive without progression. The 5-year progression-free survival (PFS) and overall survival rates were 61.5 ± 13.5% and 68.4 ± 13.1%. Patients with TP53-wild-type tumors had a 5-year PFS of 100% as compared to 28.6 ± 17.1% for TP53-mutant tumors (P = .012). Extent of resection, metastatic status, and use of radiation therapy were not significantly associated with survival. CONCLUSIONS: Non-myeloablative high-dose methotrexate-containing therapy with maximal surgical resection resulted in long-term PFS in more than half of patients with CPC. TP53-mutational status was the only significant prognostic variable and should form the basis of risk-stratification in future trials.2632-2498Liu, Anthony P Y <br />Orcid: 0000-0002-8597-9128 <br />Wu, Gang <br />Orcid: 0000-0002-1678-5864 <br />Orr, Brent A <br />Lin, Tong <br />Ashford, Jason M <br />Bass, Johnnie K <br />Bowers, Daniel C <br />Hassall, Tim <br />Fisher, Paul G <br />Indelicato, Daniel J <br />Klimo, Paul Jr <br />Boop, Frederick <br />Conklin, Heather <br />Onar-Thomas, Arzu <br />Merchant, Thomas E <br />Ellison, David W <br />Gajjar, Amar <br />Robinson, Giles W <br />Orcid: 0000-0001-7441-9486 <br />Journal Article <br />Neurooncol Adv. 2020 Dec 15;3(1):vdaa168. doi: 10.1093/noajnl/vdaa168. eCollection 2021 Jan-Dec. <br /> | en |
dc.language.iso | en | en |
dc.relation.ispartof | Neurooncol Adv | en |
dc.title | Outcome and molecular analysis of young children with choroid plexus carcinoma treated with non-myeloablative therapy: results from the SJYC07 trial | en |
dc.type | Article | en |
dc.identifier.doi | 10.1093/noajnl/vdaa168 | en |
dc.subject.keywords | high-dose methotrexate | en |
dc.subject.keywords | Tp53choroid plexus carcinoma | en |
dc.subject.keywords | infant | en |
dc.subject.keywords | clinical trial | en |
dc.identifier.risid | 3162 | en |
dc.description.pages | vdaa168 | en |
item.grantfulltext | none | - |
item.openairetype | Article | - |
item.fulltext | No Fulltext | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
Appears in Sites: | Children's Health Queensland Publications |
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.